-
Something wrong with this record ?
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis
M. Pons, S. Georgiadis, M. Østergaard, ZF. Ahmadzay, B. Glintborg, J. Heberg, SN. Christensen, S. Rasmussen, AG. Loft, I. Castrejón, F. Sánchez-Alonso, F. Iannone, D. Nordström, AM. Hokkanen, A. Ciurea, MJ. Nissen, J. Závada, K. Pavelka, Z....
Language English Country France
Document type Journal Article, Multicenter Study, Observational Study
- MeSH
- Antirheumatic Agents * therapeutic use MeSH
- Axial Spondyloarthritis * drug therapy diagnosis MeSH
- Time Factors MeSH
- Adult MeSH
- Patient Reported Outcome Measures MeSH
- Antibodies, Monoclonal, Humanized * therapeutic use MeSH
- Remission Induction MeSH
- Middle Aged MeSH
- Humans MeSH
- Follow-Up Studies MeSH
- Arthritis, Psoriatic * drug therapy diagnosis MeSH
- Registries MeSH
- Severity of Illness Index MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Geographicals
- Europe MeSH
OBJECTIVES: In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months. PATIENTS AND METHODS: Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/≥2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons of remission and LDA rates were performed by logistic regression analyses. RESULTS: The overall 24-/48-month secukinumab retention rates were 61%/51% in 767 axSpA patients, and 64%/49% in 975 PsA patients, respectively. Compared to b/tsDMARD naïve patients, a higher risk of withdrawal from secukinumab was found for those with≥2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA. Generally, remission and LDA rates were numerically higher in b/tsDMARD naïve patients. After adjustment for confounders, statistically significantly higher remission and LDA rates were found for b/tsDMARD naïve patients compared to patients with≥ 2 prior b/tsDMARDs at 24 months in axSpA and PsA. CONCLUSION: This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure.
Aberdeen Centre for Arthritis and Musculoskeletal Health University of Aberdeen Aberdeen UK
Center for Rheumatic Diseases University of Medicine and Pharmacy Bucharest Romania
Center for treatment of Rheumatic and Musculoskeletal Diseases Diakonhjemmet Hospital Oslo Norway
Centre for Rheumatology Research Landspitali University Hospital Reykjavik Iceland
DANBIO and Copenhagen Center for Arthritis Research Glostrup Denmark
Department of Clinical Medicine Aarhus University Aarhus Denmark
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
Department of Rheumatology East Tallinn Central Hospital Tallinn Estonia
Department of Rheumatology Geneva University Hospital Geneva Switzerland
Department of Rheumatology Hospital General Universitario Gregorio Marañón Madrid Spain
Department of Rheumatology Unidade Local de Saúde Santa Maria Lisbon Portugal
Department of Rheumatology University Hospital Zurich University of Zurich Zurich Switzerland
Department of Rheumatology University Medical Centre Ljubljana Ljubljana Slovenia
Departments of Medicine and Rheumatology Helsinki University Hospital Helsinki Finland
Faculty of Medicine Complutense University of Madrid Madrid Spain
Faculty of Medicine University of Iceland Reykjavik Iceland
Faculty of Medicine University of Ljubljana Ljubljana Slovenia
Institute of Rheumatology Prague Czech Republic
National Institute for Health Development Tallinn Estonia
Research Unit Sørlandet Hospital Kristiansand Norway
Research Unit Spanish Society of Rheumatology Madrid Spain
Rheumatology Radboud University Medical Center Nijmegen Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015993
- 003
- CZ-PrNML
- 005
- 20250731091424.0
- 007
- ta
- 008
- 250708s2025 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jbspin.2024.105824 $2 doi
- 035 __
- $a (PubMed)39608666
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Pons, Marion $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark
- 245 10
- $a Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis / $c M. Pons, S. Georgiadis, M. Østergaard, ZF. Ahmadzay, B. Glintborg, J. Heberg, SN. Christensen, S. Rasmussen, AG. Loft, I. Castrejón, F. Sánchez-Alonso, F. Iannone, D. Nordström, AM. Hokkanen, A. Ciurea, MJ. Nissen, J. Závada, K. Pavelka, Z. Rotar, KP. Pirkmajer, B. Michelsen, P. Mielnik, M. Bernardes, N. Khmelinskii, K. Laas, S. Vorobjov, C. Codreanu, GJ. Macfarlane, GT. Jones, B. Gudbjornsson, O. Palsson, JK. Wallman, I. van der Horst-Bruinsma, F. Onen, ML. Hetland, LM. Ørnbjerg
- 520 9_
- $a OBJECTIVES: In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months. PATIENTS AND METHODS: Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/≥2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons of remission and LDA rates were performed by logistic regression analyses. RESULTS: The overall 24-/48-month secukinumab retention rates were 61%/51% in 767 axSpA patients, and 64%/49% in 975 PsA patients, respectively. Compared to b/tsDMARD naïve patients, a higher risk of withdrawal from secukinumab was found for those with≥2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA. Generally, remission and LDA rates were numerically higher in b/tsDMARD naïve patients. After adjustment for confounders, statistically significantly higher remission and LDA rates were found for b/tsDMARD naïve patients compared to patients with≥ 2 prior b/tsDMARDs at 24 months in axSpA and PsA. CONCLUSION: This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
- 650 12
- $a antirevmatika $x terapeutické užití $7 D018501
- 650 12
- $a psoriatická artritida $x farmakoterapie $x diagnóza $7 D015535
- 650 12
- $a axiální spondyloartritida $x farmakoterapie $x diagnóza $7 D000089183
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a hodnocení výsledků péče pacientem $7 D000071066
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Georgiadis, Stylianos $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark
- 700 1_
- $a Østergaard, Mikkel $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Ahmadzay, Zohra Faizy $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Glintborg, Bente $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark; DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Heberg, Jette $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark
- 700 1_
- $a Christensen, Sara Nysom $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark
- 700 1_
- $a Rasmussen, Simon $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark
- 700 1_
- $a Loft, Anne Gitte $u Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- 700 1_
- $a Castrejón, Isabel $u Department of Rheumatology, Hospital General, Universitario Gregorio Marañón, Madrid, Spain; Faculty of Medicine, Complutense University of Madrid, Madrid, Spain
- 700 1_
- $a Sánchez-Alonso, Fernando $u Research Unit, Spanish Society of Rheumatology, Madrid, Spain
- 700 1_
- $a Iannone, Florenzo $u Rheumatology Unit, DiMePReJ, University of Bari, Bari, Italy
- 700 1_
- $a Nordström, Dan $u Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland
- 700 1_
- $a Hokkanen, Anna-Mari $u Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland
- 700 1_
- $a Ciurea, Adrian $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
- 700 1_
- $a Nissen, Michael J $u Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland
- 700 1_
- $a Závada, Jakub $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Pavelka, Karel $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Rotar, Ziga $u Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Pirkmajer, Katja Perdan $u Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Michelsen, Brigitte $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Research Unit, Sørlandet Hospital, Kristiansand, Norway
- 700 1_
- $a Mielnik, Pawel $u Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde, Førde, Norway
- 700 1_
- $a Bernardes, Miguel $u Department of Medicine, Faculty of Medicine, University of Porto, Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- 700 1_
- $a Khmelinskii, Nikita $u Department of Rheumatology, Unidade Local de Saúde Santa Maria, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon Academic Medical Centre, Lisbon, Portugal
- 700 1_
- $a Laas, Karin $u Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia
- 700 1_
- $a Vorobjov, Sigrid $u National Institute for Health Development, Tallinn, Estonia
- 700 1_
- $a Codreanu, Catalin $u Center for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Macfarlane, Gary J $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK
- 700 1_
- $a Jones, Gareth T $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK
- 700 1_
- $a Gudbjornsson, Bjorn $u Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- 700 1_
- $a Palsson, Olafur $u Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden
- 700 1_
- $a Wallman, Johan K $u Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden
- 700 1_
- $a van der Horst-Bruinsma, Irene $u Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
- 700 1_
- $a Onen, Fatos $u Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
- 700 1_
- $a Hetland, Merete Lund $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Ørnbjerg, Lykke Midtbøll $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark. Electronic address: lykke.midtboell.oernbjerg@regionh.dk
- 773 0_
- $w MED00005823 $t Joint bone spine $x 1778-7254 $g Roč. 92, č. 3 (2025), s. 105824
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39608666 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091418 $b ABA008
- 999 __
- $a ok $b bmc $g 2366683 $s 1253118
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 92 $c 3 $d 105824 $e 20241126 $i 1778-7254 $m Joint bone spine $n Joint Bone Spine $x MED00005823
- LZP __
- $a Pubmed-20250708
